Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Moxalactam (hydrolyzed) is the hydrolyzed form of moxalactam, a synthetic oxa-beta-lactam antibiotic belonging to the beta-lactam class. Moxalactam itself acts by inhibiting bacterial cell wall biosynthesis, targeting penicillin-binding proteins and thereby preventing peptidoglycan cross-linking in bacterial cell walls. The hydrolyzed form refers to its chemical breakdown product, which confers resistance to various beta-lactams via hydrolysis of the beta-lactam ring[1][4]. Moxalactam is notable for its broad-spectrum activity against Gram-positive and Gram-negative bacteria, including Enterobacteriaceae and Bacteroides fragilis; it is resistant to many beta-lactamases[2][3]. However, the hydrolyzed form does not have clinical use as an antibiotic but may be relevant in studies of resistance mechanisms or drug metabolism.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on moxalactam (hydrolyzed).